S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China

Singular Genomics Systems Stock Price, News & Analysis (NASDAQ:OMIC)

$0.42
+0.03 (+7.75%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.39
$0.42
50-Day Range
$0.33
$0.58
52-Week Range
$0.31
$3.00
Volume
173,016 shs
Average Volume
1.50 million shs
Market Capitalization
$30.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Singular Genomics Systems MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
139.8% Upside
$1.00 Price Target
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Singular Genomics Systems in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$103,822 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.46) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

327th out of 951 stocks

Analytical Instruments Industry

13th out of 29 stocks


OMIC stock logo

About Singular Genomics Systems Stock (NASDAQ:OMIC)

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

OMIC Stock Price History

OMIC Stock News Headlines

Singular Genomics Systems Founder Acquires 4.6% More Stock
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Recap: Singular Genomics Sys Q3 Earnings
OMIC Singular Genomics Systems, Inc.
Singular Genomics Systems Inc OMIC
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
Q1 2023 Singular Genomics Systems Inc Earnings Call
Q4 2022 Singular Genomics Systems Inc Earnings Call
See More Headlines
Receive OMIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OMIC
Fax
N/A
Employees
269
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.00
High Stock Price Target
$1.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+139.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-90,880,000.00
Net Margins
-3,571.18%
Pretax Margin
-3,571.18%

Debt

Sales & Book Value

Annual Sales
$760,000.00
Book Value
$2.71 per share

Miscellaneous

Free Float
57,314,000
Market Cap
$30.60 million
Optionable
Not Optionable
Beta
1.19
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Andrew Spaventa (Age 38)
    Founder, CEO, President & Chairperson of the Board
    Comp: $685.93k
  • Dr. David L. Barker Ph.D. (Age 81)
    Founder, Member of Scientific Advisory Board & Independent Director
    Comp: $63.75k
  • Dr. Eli N. Glezer Ph.D. (Age 54)
    Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
    Comp: $496.5k
  • Mr. Dalen Meeter (Age 45)
    Chief Financial Officer
    Comp: $434.39k
  • Jyotsna Ghai
    Chief Operating Officer
  • Mr. Jorge Velarde Jr. (Age 56)
    MBA, Senior Vice President of Corporate Development & Strategy
  • Mr. Jeff Bullard
    Head of Sales
  • Mr. Vincent Brancaccio (Age 40)
    Head of Human Resources
  • Mr. Samuel Ropp Ph.D. (Age 49)
    Chief Commercial Officer














OMIC Stock Analysis - Frequently Asked Questions

Should I buy or sell Singular Genomics Systems stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares.
View OMIC analyst ratings
or view top-rated stocks.

What is Singular Genomics Systems' stock price target for 2024?

1 analysts have issued 1 year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 139.8% from the stock's current price.
View analysts price targets for OMIC
or view top-rated stocks among Wall Street analysts.

How have OMIC shares performed in 2023?

Singular Genomics Systems' stock was trading at $2.01 at the beginning of the year. Since then, OMIC shares have decreased by 79.3% and is now trading at $0.4170.
View the best growth stocks for 2023 here
.

Are investors shorting Singular Genomics Systems?

Singular Genomics Systems saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,540,000 shares, an increase of 40.0% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 600,400 shares, the short-interest ratio is currently 2.6 days. Approximately 3.7% of the company's stock are sold short.
View Singular Genomics Systems' Short Interest
.

When is Singular Genomics Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our OMIC earnings forecast
.

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, November, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. Singular Genomics Systems had a negative net margin of 3,571.18% and a negative trailing twelve-month return on equity of 40.38%.

When did Singular Genomics Systems IPO?

(OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank acted as the underwriters for the IPO.

Who are Singular Genomics Systems' major shareholders?

Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.82%), UBS Group AG (3.02%), QVIDTVM Management LLC (1.63%), Acuitas Investments LLC (0.71%), Platinum Investment Management Ltd. (0.58%) and Jacobs Levy Equity Management Inc. (0.49%). Insiders that own company stock include Andrew Spaventa, Eli N Glezer, James E Flynn, Kim P Kamdar, Michael J Pellini and Sheryl L Conley.
View institutional ownership trends
.

How do I buy shares of Singular Genomics Systems?

Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OMIC) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -